Overview of the Upcoming General Meeting
Inventiva, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for metabolic dysfunction, has announced its Combined General Meeting. This important meeting provides shareholders with vital information about the company's progress and future direction.
Meeting Details and Participation
Shareholders are encouraged to engage in the Combined General Meeting, taking place at 9 a.m. CEST. While the specific venue details are not mentioned here, participants can prepare to discuss significant aspects of the company.
Availability of Preparatory Documents
The preliminary materials for this Combined General Meeting are now accessible for shareholders. These documents include the meeting agenda and proposed resolutions, ensuring that all participants are well informed before the event. Significant preparations have gone into making this information available.
Documentation Accessibility
With the adherence to French regulations, key documents will be available at the company’s registered office in Daix. This proactive approach reflects Inventiva’s commitment to transparency. Shareholders holding registered shares may request these documents up to five days before the meeting, facilitating their participation.
Contacting the Company for Information
Any shareholder can consult the necessary documents by reaching out via email to the company. This open line of communication underlines Inventiva's approach to shareholder engagement, ensuring that everyone has the chance to voice concerns or request information.
About Inventiva
Inventiva is at the forefront of developing oral small molecule therapies aimed at treating patients with metabolic dysfunctions associated with conditions like MASH. Their lead product, lanifibranor, is being evaluated in the pivotal Phase 3 clinical trial for its effectiveness against this progressive liver disease.
With a dynamic team of approximately 90 skilled professionals, Inventiva emphasizes innovation and thorough research. Their impressive library of pharmacologically relevant molecules bolsters their capabilities in drug development.
Company Listings and Investor Relations
As a public company, Inventiva trades on the Euronext Paris under the ticker IVA and is also listed on the Nasdaq Global Market. This dual listing helps broaden their investor base and enhance visibility among potential investors.
Conclusion
In summary, the upcoming Combined General Meeting represents a significant opportunity for shareholders to engage with the company and gather insights on its ongoing developments and future initiatives. Inventiva's proactive approach to providing documentation and facilitating communication highlights its commitment to its stakeholders.
Frequently Asked Questions
What is the purpose of the Combined General Meeting?
The meeting aims to inform shareholders about company updates and gather feedback on proposed resolutions.
How can shareholders access the preparatory documents?
Documents are available at the company’s registered office and online on Inventiva’s website starting from a designated date.
Who can participate in the General Meeting?
All shareholders of Inventiva can participate, and those holding registered shares can request supporting documents to be sent to them.
What is the main focus of Inventiva's research?
The company primarily focuses on developing treatments for metabolic dysfunction-related diseases like MASH.
How can shareholders contact Inventiva?
Shareholders can reach out via email for inquiries or document requests, promoting open communication.
